Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
Annals of Nuclear Medicine|February 20, 2013
Serum tumor markers and PET/CT imaging for tumor recurrence detectionVibeke Kruse, Veronique Cocquyt, Marleen Borms, et al.
Cornea|May 27, 2020
Bilateral Corneal Graft Rejection Associated With Pembrolizumab TreatmentEva Vanhonsebrouck, Mieke Van De Walle, Willem Lybaert, et al.
Frontiers in Bioengineering and Biotechnology|March 9, 2023
Biocontainment strategies for in vivo applications of Saccharomyces boulardiiKarl Alex Hedin, Vibeke Kruse, Ruben Vazquez-Uribe, et al.
Melanoma Research|April 4, 2022
A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitorsGil Awada, Julia Katharina Schwarze, Jens Tijtgat, et al.
Springerplus|May 28, 2013
The addition of bevacizumab to standard chemotherapy in breast cancer: which patient benefits the most?Vibeke Kruse, Hannelore Denys, Rudy Van Den Broecke, et al.
European Journal of Hospital Pharmacy : Science and Practice|June 4, 2019
The impact of logarithmic dose banding of anticancer drugs on pharmacy compounding efficiency at Ghent University HospitalBarbara Claus, Kaat De Pourcq, Nele Clottens, et al.
Neurochemical Research|April 3, 2002
NS-417, a novel compound with neurotrophic-like effectsLone Dagø, Dan Peters, Morten Meyer, et al.
The Lancet. Oncology|March 8, 2017
Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trialMax Schreuer, Yanina Jansen, Simon Planken, et al.
Acta Clinica Belgica|July 31, 2019
To treat or not to treat? Managing comorbidities in cancer patients under immune checkpoint inhibitionStijn De Keukeleire, Tijl Vermassen, Gert De Schoenmakere, et al.
JAMA Dermatology|December 22, 2016
Cost-effectiveness and Budget Effect Analysis of a Population-Based Skin Cancer ScreeningLore Pil, Isabelle Hoorens, Katrien Vossaert, et al.
Pageof 4